Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : Revenue Falls; Full-Year Sales Seen Below Wall Street Expectations

share with twitter share with LinkedIn share with facebook
share via e-mail
01/31/2017 | 08:38am EDT
By Austen Hufford 

Pfizer Inc. on Tuesday said revenue declined in its latest quarter, and the company gave an outlook for full-year revenue below Wall Street's expectations.

Shares of the company fell 1.3% in premarket trading.

Global sales of pneumonia vaccines Prevnar and related drugs fell 24%. In the U.S., Prevnar 13 revenue fell by a third due to high initial rates vaccination rates in previous years and a smaller and unfavorable timing of government purchases.

Sales of cancer drug Ibrance doubled to $643 million

Total Viagra revenue fell 12% to $381 million. Lipitor revenue, meanwhile, rose 2% to $464 million.

For the year, Pfizer now expects revenue of $52 billion to $54 billion and adjusted earnings per share of $2.50 to $2.60. Analysts polled by Thomson Reuters had expected revenue of $54.03 billion and $2.56 in per-share earnings.

For its latest quarter, Pfizer reported a profit of $775 million, or 13 cents a share, up from a loss of $172 million, or 3 cents a share, a year prior. The previous year's quarter included charges related to a settlement over allegations that one of its units overcharged government Medicaid health programs and related to devaluations in Venezuela related to the country's financial crisis.

On an adjusted basis, earnings were 47 cents a share, down from 53 cents. Revenue fell 3% to $13.63 billion.

Analysts polled by Thomson Reuters had forecast adjusted earnings of 50 cents a share on revenue of $13.63 billion.

R&D costs rose 7% as selling, informational and administrative expenses fell 12%.

Write to Austen Hufford at austen.hufford@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
08:45aOPKO Health Up 12% After Study Data
10/18PFIZER : Statement on Vincristine Sulfate Injection, USP Supply in the United St..
10/17PFIZER : Description Amended Statement of Changes in Beneficial Ownership
10/17PFIZER : Description Statement of Changes in Beneficial Ownership
10/15Health-Care Stocks Get a Welcome Respite -- Update
10/15Health-Care Stocks Get a Welcome Respite
10/15Elizabeth Warren's Rise Is Battering Health-Care Stocks
10/15Elizabeth Warren's Rise Is Battering Health-Care Stocks
10/14Health Care Flat As Traders Seek Out Defensive Sectors -- Health Care Roundup
10/14PFIZER : Presents Positive Phase 3 Data at the 28th Congress of the European Aca..
More news
Financials (USD)
Sales 2019 51 469 M
EBIT 2019 18 958 M
Net income 2019 13 771 M
Debt 2019 32 534 M
Yield 2019 3,93%
P/E ratio 2019 16,5x
P/E ratio 2020 18,2x
EV / Sales2019 4,55x
EV / Sales2020 4,93x
Capitalization 202 B
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 43,15  $
Last Close Price 36,46  $
Spread / Highest target 50,9%
Spread / Average Target 18,4%
Spread / Lowest Target 1,48%
EPS Revisions
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Mikael Dolsten Chief Scientific Officer
Lidia L. Fonseca Chief Technology Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-16.47%201 662
JOHNSON & JOHNSON-1.05%337 021
ROCHE HOLDING AG18.88%250 869
MERCK AND COMPANY10.82%216 813
NOVARTIS15.10%198 751
NOVO NORDISK AS17.69%123 560